Highlights Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			5-day change	1st Jan Change
303.05 ^USD	-0.19%		+0.35%	-23.79%

06-03	Alnylam, Inceptive sign up to $2 billion AI drug discovery deal	RE
06-03	Alnylam Pharmaceuticals Strikes Up to $2 Billion AI Collaboration With Inceptive Nucleics	MT

Highlights

06-03	Alnylam Pharmaceuticals Strikes Up to $2 Billion AI Collaboration With Inceptive Nucleics	MT
06-03	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics	CI
05-12	Alnylam Pharmaceuticals, Inc. Announces New Analyses from the Helios-B Phase 3 Study of Vutrisiran in Patients	CI
04-30	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Alnylam Pharmaceuticals Q1 Adjusted Net Income, Revenue Rise; Reiterates 2026 Product Revenue Guidance -- Shares Up Pre-Bell	MT
04-30	(ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.90B - $5.30B	MT
04-30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q1 Revenue $1.17B, vs. FactSet Est of $1.12B	MT
04-30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $1.99 per Share	MT
03-30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI
03-24	Alnylam Pharmaceuticals, Inc. Advances ATTR-CM Care with Strategic Collaboration and AI-Enabled Pathways	CI
03-24	Alnylam Pharmaceuticals, Viz.ai Collaborate on AI-Enabled Detection of Transthyretin Amyloidosis	MT
03-02	Intellia gets FDA nod to resume second gene therapy trial after safety pause	RE
02-12	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-12	Alnylam Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Issues 2026 Outlook	MT
02-12	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $1.25 per Share	MT
02-12	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q4 Revenue $1.10B, vs. FactSet Est of $1.15B	MT
01-11	Alnylam Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2026	CI
12-17	Alnylam Pharmaceuticals, Inc. Announces to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics	CI
12-11	Alnylam announces partial repurchase of 1.00% convertible senior notes due 2027	RE
12-11	Alnylam Pharmaceuticals Signs Redemption Deals for Certain 1% Senior Notes Due 2027	MT
11-08	Alnylam Pharmaceuticals, Inc. Announces Results from New Post Hoc Analysis of the Helios-B Phase 3 Study of Vutrisiran	CI
30/10/25	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
30/10/25	Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2025	CI
30/10/25	Alnylam beats Q3 revenue estimates, up FY forecast	RE
30/10/25	Alnylam Pharmaceuticals Swings to Q3 Non-GAAP Earnings, Revenue Increases	MT